PMID- 28812918
OWN - NLM
STAT- MEDLINE
DCOM- 20190916
LR  - 20221226
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 5
DP  - 2018 May
TI  - Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a 
      meta-analysis of randomized controlled trials.
PG  - 795-803
LID - 10.1080/03007995.2017.1368466 [doi]
AB  - BACKGROUND AND AIMS: Radioiodine-refractory advanced or metastatic thyroid cancer 
      has poor prognosis. We conducted a meta-analysis of randomized controlled trials 
      to evaluate the effectiveness and safety of tyrosine kinase inhibitors (TKIs) for 
      advanced or metastatic thyroid cancer treatment. METHODS: Studies published up to 
      April 2017 were selected. The pooled effect size was calculated through 
      meta-analysis by using random effects models. Outcomes were overall survival 
      (OS), progression-free survival (PFS), objective response rate (RR), and adverse 
      events (AEs). RESULTS: Six studies examining 1615 patients were included. TKI 
      treatment significantly improved PFS in patients with differentiated thyroid 
      cancer (DTC; hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.23-0.82) 
      and those with medullary thyroid cancer (MTC; HR = 0.36; 95% CI, 0.22-0.58). TKI 
      treatment significantly prolonged OS in patients with DTC (HR = 0.74; 95% CI, 
      0.58-0.95). The TKI treatment group exhibited a significantly improved partial 
      response rate (risk ratio = 15.8; 95% CI, 1.77-140.69) but a significantly higher 
      number of AEs compared with the control group. CONCLUSION: TKIs significantly 
      improved PFS and RR in patients with advanced or metastatic DTC or MTC. We 
      recommend thoroughly evaluating patients' health status and cautiously using TKIs 
      to maximize their benefits and minimize their toxicity.
FAU - Liu, Jen-Wei
AU  - Liu JW
AD  - a Department of Pharmacy , Shin Kong Wu Ho-Su Memorial Hospital , Taipei , 
      Taiwan.
AD  - b School of Pharmacy , College of Pharmacy, Taipei Medical University , Taipei , 
      Taiwan.
FAU - Chen, Chiehfeng
AU  - Chen C
AD  - c Cochrane Taiwan , Taipei Medical University , Taipei , Taiwan.
AD  - d Department of Public Health , School of Medicine, College of Medicine, Taipei 
      Medical University , Taipei , Taiwan.
AD  - e Division of Plastic Surgery, Department of Surgery , Wan Fang Hospital, Taipei 
      Medical University , Taipei , Taiwan.
FAU - Loh, El-Wui
AU  - Loh EW
AD  - f Center for Evidence-Based Health Care , Shuang Ho Hospital, Taipei Medical 
      University , New Taipei City , Taiwan.
FAU - Chu, Chun-Cheng
AU  - Chu CC
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Wang, Mu-Yi
AU  - Wang MY
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Ouyang, Hsin-Ju
AU  - Ouyang HJ
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Chang, Ya-Ting
AU  - Chang YT
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Zhuang, Wei-Zhan
AU  - Zhuang WZ
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Chou, Ching-Wen
AU  - Chou CW
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Huang, Der-Jr
AU  - Huang DJ
AD  - g School of Medicine , College of Medicine, Taipei Medical University , Taipei 
      City , Taiwan.
FAU - Lee, Chia-Hwa
AU  - Lee CH
AD  - h School of Medical Laboratory Science and Biotechnology , College of Medical 
      Science and Technology, Taipei Medical University , Taipei , Taiwan.
AD  - i Comprehensive Cancer Center of Taipei Medical University , Taipei , Taiwan.
AD  - j Department of Laboratory Medicine , Shuang Ho Hospital, Taipei Medical 
      University , Taipei , Taiwan.
FAU - Yen, Yun
AU  - Yen Y
AD  - k Graduate Institute of Cancer Biology and Drug Discovery , College of Medical 
      Science and Technology, Taipei Medical University , Taipei , Taiwan.
FAU - Tam, Ka-Wai
AU  - Tam KW
AD  - c Cochrane Taiwan , Taipei Medical University , Taipei , Taiwan.
AD  - l Department of Surgery , School of Medicine, College of Medicine, Taipei Medical 
      University , Taipei , Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20170912
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
CIN - Curr Med Res Opin. 2022 Oct;38(10):1769-1770. PMID: 35621192
CIN - Curr Med Res Opin. 2022 Oct;38(10):1771. PMID: 35993277
MH  - *Antineoplastic Agents/adverse effects/therapeutic use
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology
MH  - Humans
MH  - *Protein Kinase Inhibitors/adverse effects/therapeutic use
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - *Thyroid Neoplasms/drug therapy/mortality
OTO - NOTNLM
OT  - Tyrosine kinase inhibitors
OT  - meta-analysis
OT  - radioiodine refractory
OT  - targeted therapy
OT  - thyroid cancer
EDAT- 2017/08/17 06:00
MHDA- 2019/09/17 06:00
CRDT- 2017/08/17 06:00
PHST- 2017/08/17 06:00 [pubmed]
PHST- 2019/09/17 06:00 [medline]
PHST- 2017/08/17 06:00 [entrez]
AID - 10.1080/03007995.2017.1368466 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 May;34(5):795-803. doi: 10.1080/03007995.2017.1368466. 
      Epub 2017 Sep 12.